DK1679319T3 - Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD) - Google Patents

Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD)

Info

Publication number
DK1679319T3
DK1679319T3 DK05107898T DK05107898T DK1679319T3 DK 1679319 T3 DK1679319 T3 DK 1679319T3 DK 05107898 T DK05107898 T DK 05107898T DK 05107898 T DK05107898 T DK 05107898T DK 1679319 T3 DK1679319 T3 DK 1679319T3
Authority
DK
Denmark
Prior art keywords
arg
glu
asp
tyr
phe
Prior art date
Application number
DK05107898T
Other languages
English (en)
Inventor
Frank Mattner
Original Assignee
Frank Mattner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank Mattner filed Critical Frank Mattner
Application granted granted Critical
Publication of DK1679319T3 publication Critical patent/DK1679319T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
DK05107898T 2003-01-14 2004-01-13 Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD) DK1679319T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT362003 2003-01-14
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
PCT/EP2004/000162 WO2004062556A2 (en) 2003-01-14 2004-01-13 Methods for preventing and treating alzheimer’s disease (ad)

Publications (1)

Publication Number Publication Date
DK1679319T3 true DK1679319T3 (da) 2008-01-28

Family

ID=32714004

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04701585.4T DK1583774T3 (da) 2003-01-14 2004-01-13 Fremgangsmåder til forebyggelse og behandling af alzheimers sygdom
DK05107898T DK1679319T3 (da) 2003-01-14 2004-01-13 Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04701585.4T DK1583774T3 (da) 2003-01-14 2004-01-13 Fremgangsmåder til forebyggelse og behandling af alzheimers sygdom

Country Status (15)

Country Link
US (2) US7732568B2 (da)
EP (2) EP1679319B1 (da)
JP (2) JP4547373B2 (da)
CN (2) CN1826354B (da)
AT (3) AT413945B (da)
CA (1) CA2513218C (da)
CY (2) CY1107146T1 (da)
DE (2) DE602004025668D1 (da)
DK (2) DK1583774T3 (da)
ES (2) ES2339447T3 (da)
HK (1) HK1091499A1 (da)
PL (1) PL209989B1 (da)
PT (2) PT1583774E (da)
SI (1) SI1583774T1 (da)
WO (1) WO2004062556A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010435A1 (en) 2002-12-19 2007-01-11 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20070172496A1 (en) * 2004-01-28 2007-07-26 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2015111675A (ru) * 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
KR101605207B1 (ko) * 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CN101820911B (zh) * 2007-06-12 2015-05-06 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
EP2238166B1 (en) * 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
NZ585110A (en) * 2007-10-05 2012-09-28 Genentech Inc Method and compositions for diagnosis and treatment of amyloidosis
US8586706B2 (en) 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
EP2224000B1 (en) * 2007-10-29 2020-05-13 TAO Health Life Pharma Co., Ltd. Antibody and use thereof
CA2759118A1 (en) 2008-04-17 2009-10-22 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
AT509611B1 (de) * 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
CA2723995A1 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
SI2579042T1 (sl) 2011-10-04 2014-09-30 Affiris Ag Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
US10381614B2 (en) * 2013-04-17 2019-08-13 Samsung Sdi Co., Ltd. Battery module
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2017076873A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
CN105237628B (zh) * 2015-11-17 2018-08-07 南开大学 一种用于治疗阿尔兹海默症的多肽
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6088993A (en) 1999-02-05 2000-07-18 Irace; Francisco D. Closure system
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
EP1180938B1 (en) * 1999-09-03 2010-03-24 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents, compositions and methods utilizing the same useful in treating or preventing alzheimer disease
PL365424A1 (en) 2000-03-03 2005-01-10 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
DE50111493D1 (de) 2001-09-03 2007-01-04 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Antigen-Mimotope und Vakzine gegen Krebserkrankungen
EP1788394B1 (en) * 2002-05-07 2009-06-17 Institut Pasteur Screening for peptides inhibiting PP1c binding to Bcl-2, BCL-Xl and BCL-W proteins

Also Published As

Publication number Publication date
CN1826354A (zh) 2006-08-30
DE602004025668D1 (de) 2010-04-08
WO2004062556A8 (en) 2004-10-21
JP5282058B2 (ja) 2013-09-04
CA2513218A1 (en) 2004-07-29
CY1110634T1 (el) 2015-04-29
JP2010174024A (ja) 2010-08-12
ATA14642003A (de) 2005-11-15
WO2004062556A3 (en) 2004-09-16
WO2004062556A2 (en) 2004-07-29
JP4547373B2 (ja) 2010-09-22
PL378333A1 (pl) 2006-03-20
AT413945B (de) 2006-07-15
SI1583774T1 (sl) 2010-06-30
DE602004009705D1 (de) 2007-12-06
PL209989B1 (pl) 2011-11-30
EP1679319B1 (en) 2007-10-24
ATE458753T1 (de) 2010-03-15
ES2339447T3 (es) 2010-05-20
PT1679319E (pt) 2008-01-10
ES2339447T8 (es) 2011-05-26
US7732568B2 (en) 2010-06-08
EP1583774B1 (en) 2010-02-24
US20110015131A1 (en) 2011-01-20
CA2513218C (en) 2013-06-25
CN102526699A (zh) 2012-07-04
ATE376559T1 (de) 2007-11-15
US20060111301A1 (en) 2006-05-25
CN1826354B (zh) 2014-01-08
AU2004204349A1 (en) 2004-07-29
ES2296084T3 (es) 2008-04-16
EP1583774A2 (en) 2005-10-12
DE602004009705T2 (de) 2008-06-05
EP1679319A1 (en) 2006-07-12
CY1107146T1 (el) 2012-05-23
JP2006515876A (ja) 2006-06-08
PT1583774E (pt) 2010-04-07
HK1091499A1 (en) 2007-01-19
DK1583774T3 (da) 2010-05-03

Similar Documents

Publication Publication Date Title
DK1679319T3 (da) Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD)
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
AT500379B8 (de) Tau-proteine
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
DK2075007T3 (da) Behandling af Alzheimers sygdom
MA28418B1 (fr) Anticorps liant un recepteur de l'interleucine 4
NO20076021L (no) Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
EP2628750A3 (en) Targeted identification of immunogenic peptides
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
ATE395356T1 (de) Oberflächenprotein aus neisserien
WO2007030771A3 (en) Targeted identification of immunogenic peptides
WO2004053117A3 (en) Serine protease
DK1569961T3 (da) Splice variant af det menneskelige hypofysevæksthormon
ATE338063T1 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers
WO2002070560A3 (en) Nuclear hormone receptor ligand binding domain